Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Directors' Options

1 Oct 2012 07:00

RNS Number : 5255N
Sopheon PLC
01 October 2012
 



FOR IMMEDIATE RELEASE

1 October 2012

 

SOPHEON PLC

 

GRANT OF OPTIONS

 

Sopheon plc ("Sopheon" or " the Company") announces that it has granted options over ordinary shares of 5 pence each in the share capital of the Company ("Ordinary Shares") to certain directors. These grants are part of a wider grant of options over 5,285,598 Ordinary Shares, to both new and existing staff members.

 

Of this total, options over 285,000 Ordinary Shares have been granted to new members of staff. The remaining 5,000,598 have been granted to members of staff that have been with the company for ten years or longer. This second category represents the replacement of options previously granted to these members of staff approximately ten years ago, of which 146,112 lapsed in 2011 and 4,854,486 have lapsed in 2012 or are due to lapse in 2013. As part of this event, the options due to lapse in 2013 have been cancelled. Accordingly, the vast majority of this category can be considered as replacement or continuation of options in existence at December 31, 2011 and included in our financial statements as of that date.

 

Four directors are involved in this event. Barry Mence has been granted options over 122,500 ordinary shares, Andrew Michuda over 2,767,594, Arif Karimjee over 462,500 and Bernard Al over 25,000 ordinary shares. Following this grant, Barry Mence has options over a total of 485,000 ordinary shares, Andrew Michuda over 3,997,000, Arif Karimjee over 1,150,000 and Bernard Al over 25,000 ordinary shares.

 

All the options will vest evenly over 3 years, and are exercisable up to 10 years from the date of grant. The options have been granted at a price of 5.25 pence per share, being the mid-market closing price on AIM on 28 September 2012.

 

Chairman Barry Mence said:

 

"We are proud of the fact that we have so many staff that have been with us for ten years or longer, and have shown such commitment to our company and our vision. It is right that share option incentives which are due to lapse without exercise are renewed, with vesting conditions designed to encourage continued commitment to the company."

 

For further information contact:

 

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Henrik Persson / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Guy McDougall / Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) is an international provider of software and services. Sopheon's solutions structure, align and manage innovation processes to help organizations generate more revenues and profits from new products. Sopheon's solutions are used by industry leaders throughout the world, including BASF, Corning, Electrolux, Honeywell, Lockheed Martin, Philips and SABMiller. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com. 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAXNPAEEAEFF
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.